---
title: CDMOs offering Monoclonal Antibody (mAb) Manufacturing with Cell Therapy
path: /explore/monoclonal-antibody-manufacturing/cell-therapy
companies_count: 13
---

# CDMOs offering Monoclonal Antibody (mAb) Manufacturing with Cell Therapy

13 published CDMOs match Monoclonal Antibody (mAb) Manufacturing and Cell Therapy.

Locations in this set include United States, Japan, United Kingdom, China, Denmark, and Germany.

Capabilities that show up most often in this set: CMC Analytical Development, Process Development, Recombinant Protein Manufacturing, Quality Control Testing, and Technology Transfer.

## Matching companies

- [AGC Biologics](/companies/agcbio)
  - Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- [Asimov](/companies/asimov)
  - Asimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.
- [Boston Institute of Biotechnology, LLC](/companies/bostonbib)
  - Full-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.
- [Catalent](/companies/catalent)
  - Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
- [Charles River Laboratories](/companies/criver)
  - Charles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
- [Dr. Reddy's Laboratories](/companies/drreddys)
  - Integrated global pharmaceutical company manufacturing generics, APIs, biosimilars, and innovative medicines across 66 countries with capabilities in small molecule and biologics development and manufacturing.
- [FUJIFILM Biotechnologies](/companies/fujifilm-biotechnologies)
  - CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.
- [Lonza Cell & Gene Technologies](/companies/lonza)
  - Lonza is the world's leading CDMO, founded in Switzerland in 1897, serving the healthcare industry with integrated offerings for contract development and manufacturing of therapies across multiple modalities.
- [Minaris Advanced Therapies](/companies/wuxi-advanced-therapies)
  - Pure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
- [National Resilience](/companies/resilience)
  - End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [Symbiosis Pharmaceutical Services](/companies/symbiosis-pharma)
  - UK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.